Changing Trends of Breast Cancer Survival in Sultanate of Oman
Table 1
Clinical features and treatment modalities used for all 122 patients with invasive breast cancer in Oman between January 2003 and December 2008.
Clinical characteristics
Number
Percentage
Number
Percentage
Period 2003–2008
Period 1996–2002
Gender
Female
119
97.5
150
98.7
Male
3
2.5
2
1.3
Age
40
39
32
31
20.4
41–50
36
29.5
46
30.3
51–60
31
25.4
49
32.2
60
16
13.1
26
17.1
Menopausal status (women)
Premenopausal
68
57.1
72
48.0
Menopausal
51
42.8
78
52.0
Side of involved breast
Left
65
53.2
74
48.7
Right
54
44.3
76
50.0
Bilateral
3
2.5
2
1.3
Surgery
Modified radical mastectomy
68
55.7
100
65.8
Breast conservation surgery
43
35.2
40
26.3
Lumpectomy or biopsy only
—
—
12
7.9
Surgery not done (patient refusal or stage IV disease)
11
9
—
—
Chemotherapy
Neoadjuvant
29
23.7
20
13.2
Adjuvant
65
53.2
65 (17)
42.8
FEC
26
40
44
AC Docetaxel trastuzumab
24
37
4
Miscellaneous (AC, Paclitaxel, TAC, or CMF)
15
23
11 (4)
Palliative
18
14.75
—
—
Chemotherapy refused
7
5.73
—
—
Missing information
3
2.45
—
—
Radiotherapy
90
73.8
96
63.1
Hormone treatment
Tamoxifen or Aromatase inhibitors
85
69.7
115
75.7 (9.3)
A = Adriamycin, C = Cyclophosphamide, E = Epirubicin, F = Fluorouracil, M = Methotrexate, T = Docetaxel. AC/FEC followed by paclitaxel or docetaxel ± trastuzumab, where indicated. All received anthracycline (AC/FEC/FAC) regimens, The numbers in brackets refer to patients with metastatic disease treated with chemotherapy and/or hormonal treatment. All these patients were treated with anthracycline-based regimens (AC/FEC/FAC). All but 3 patients were treated with tamoxifen; aromatase inhibitors were not in use during that period. 3 patients were treated with goserelin.
